QMS Medical Allied Services (QMS MAS) has acquired a 51 per cent stake in Saarathi Healthcare, marking a significant strategic expansion for the company.
QMS MAS, known for its Patient Service Programs (PSP) and diagnostic devices, aims to enhance its offerings with the acquisition of Saarathi Healthcare. QMS MAS provides advanced diagnostic tests for diseases like Osteoporosis, Diabetes, COPD, and Hypertension across India, promoting early intervention. Saarathi Healthcare, with a 15-year history and over 1000 projects, excels in patient and disease management, offering support in oncology, hepatology, chronic kidney disease, rare diseases, child growth, and maternal health, significantly improving outcomes.
The company in a press statement further said that the acquisition aligns with QMS MAS's strategic priorities to expand its total addressable market in the value-added patient services vertical of the healthcare industry.
“The acquisition of Saarathi is the natural extension of our services and another step of our expansion plan. Where QMS MAS specialises in patient screening, Saarathi specialises in disease management leading to better disease outcomes, essentially enabling us to provide a comprehensive portfolio to our clients. This move will have a significant addition to our revenues and profitability from the onset of the next fiscal year,” said Mahesh Makhija, CMD of QMS Medical Allied Services .
Expressing enthusiasm about the merger, Ranjeeta Vinil, Founder & CEO of Saarathi Healthcare, stated, “We are thrilled to be merging with QMS MAS. This means we will forge ahead with collective strength in products and services. This will give synergies in our services that will benefit patients greatly and also contribute to better outcomes.”
